Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Robert Meadowcroft

Chief Executive, Muscular Dystrophy UK

Recent stories

  • The government needs to get on with its own recommendations and speed up access to life-changing drugsSubscription

    10 JUL 2017

    As the rest of Europe competes to rehome the European Medicines Agency (EMA) from London, minds at home are finally focusing on what that means for access to new treatments in a post-Brexit Britain. The warnings have been clear: without an effective relationship with the EMA, there is a risk that Britain will fall to the back of the queue when it comes to accessing new drugs. And there are a lot of new treatments that could prolong and change lives, particularly for rare conditi

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.